Key Highlights

  • Eton shares are trading down 1.48% at $51.41, against a previous close of $52.18.
  • ET-900 will test mecasermin in infantile spasms, with first dosing planned for Q1 2027.
  • Third-quarter results are due Nov. 5, with consensus near $42.2 million in revenue.

Eton (NASDAQ:ETON) shares are trading down 1.48% at $51.41, against a previous close of $52.18, after the company announced ET-900, a new program testing mecasermin for infantile and epileptic spasms. The stock has pulled back from its 52-week high of $66.37 but is still up roughly 200% so far this year.

Eton Pharmaceuticals, based in Deer Park, Illinois, is a specialty pharmaceutical company incorporated in 2017 that develops, acquires and commercializes treatments for rare diseases. It sells about ten products under its own label through an internal sales force and specialty pharmacy and distributor channels, including Increlex, Alkindi Sprinkle, Khindivi, Galzin, Desmoda, Hemangeol and PKU Golike. Its late-stage candidates include Amglidia, ET-700, ET-800 and the Zeneo hydrocortisone autoinjector.

ET-900 Extends Eton Into Pediatric Neurology

ET-900 is built around mecasermin, the active ingredient in Increlex, which Eton already sells. The company licensed IGF-1 Patent rights from Baylor College of Medicine and has filed an IND for an investigator-sponsored Phase 2 study, with first dosing planned for the first quarter of 2027.

Mecasermin is a recombinant form of insulin-like growth Factor 1, and Eton has about 44 employees, so the program builds on an asset already in its portfolio.

The program fits the company's planned entry into pediatric neurology and applies an ingredient it already commercializes to a new rare-disease setting. As an early program, ET-900 carries no efficacy data yet, and the Phase 2 study is the first step in showing whether the approach works in infantile and epileptic spasms.

Strong Growth Sets the Backdrop

Eton's second-quarter 2026 Revenue rose 99% from a year earlier to a record $37.6 million, with Net Income of $11.6 million and adjusted EBITDA of $16.2 million, a 43% margin. Management raised 2026 revenue guidance to more than $145 million and an adjusted EBITDA Margin of at least 35%.

Trailing Earnings Per Share are $0.38 and the 52-week range runs from $14.27 to $66.37, which shows how far the shares have moved over the year. Forward and trailing price-to-earnings ratios of 32.02 and 133.54 reflect a company whose earnings are still scaling quickly.

Third-Quarter Results Are the Next Test

Eton reports third-quarter results on Nov. 5 after the close. Consensus calls for revenue of about $42.2 million and earnings of $0.34 per share, and analysts' average target sits near $71.50. The market will compare those figures with the raised guidance and look for any change to the full-year outlook.

The slight decline after the ET-900 announcement points to a stock that is consolidating ahead of earnings rather than reacting to the news. For investors, the key questions are whether sales of existing products keep growing at the rate set in the second quarter, how much the new program will add to research spending, and when the Phase 2 study begins enrolling.